Vaccine specialist SK Bioscience narrowed its operating loss in the second quarter while expanding its global business and vaccine pipeline to facilitate future growth. The company said in a regulatory filing Monday that its revenue stood at 155.7 billion won ($110 million) in the April-June period, down 3.8 percent from a year earlier. Its operating loss narrowed to 15.7 billion won from 37.4 billion won during the same period. The company attributed the slight decline in second-quarter revenue to a temporary delay in the supply schedule for some of its vaccines. As the shipments pushed back to the third quarter, the entire delayed volume is expected to be reflected in third-quarter results, limiting the impact on its full-year performance. The company said its profitability improvement was largely driven by IDT Biologika, a German contract development and manufacturing organization (CDMO) that SK Bioscience acquired in 2024. IDT Biologika improved its earnings as production volumes increased for major clients, while costs declined through workforce optimization and higher production yi